Plasma from some cancer patients inhibits adenoviral Ad5f35 vector transduction of dendritic cells

Published:April 11, 2018DOI:



      Pooled AB serum is often used as a media supplement for cell culture but it has the potential to transmit infectious diseases. To avoid this risk, we used autologous plasma as a media supplement for manufacturing dendritic cells (DCs) for cancer immunotherapy. We noticed inconsistencies in the DCs and investigated their nature and cause.


      Adenovirus human epidural growth factor receptor 2 (adHER2/neu) DCs for 21 patients were manufactured from autologous peripheral blood monocytes that were treated with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-4 for 3 days, transduced with Ad5f35HER2ECTM and then treated with lipopolysaccharide and interferon (IFN)-γ for 1 day. The cells were cultured in RPMI-1640 supplemented with either 10% heat inactivated autologous or AB plasma.


      Twenty-eight adHER2/neu DCs were manufactured for 21 patients using autologous plasma and 68 were manufactured for 20 of those patients using AB plasma. The expression of human epidural growth factor receptor 2 (HER2/neu) was less for DCs manufactured with autologous plasma (70.3 ± 33.3% versus 86.1 ± 22.8%; P <0.01). Manufacturing adHER2/neu DCs using monocytes from three healthy subjects and plasma from one patient with low HER2/neu expression (18%) resulted in low HER2/neu expression by all three DCs (13%, 16% and 23%). Analysis of the levels of 1322 proteins in eight plasma samples associated with low HER2/neu expression and in 12 associated with high HER2/neu expression revealed that the levels of 14 predicted HER2/neu transduction efficiency.


      The manufacture of adHER2/neu DC using autologous plasma as a media supplement resulted in inconsistent HER2/neu expression. It is likely that variability in the levels of multiple proteins in autologous plasma contributed to low HER2/neu expression.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Selvaggi T.A.
        • Walker R.E.
        • Fleisher T.A.
        Development of antibodies to fetal calf serum with arthus-like reactions in human immunodeficiency virus-infected patients given syngeneic lymphocyte infusions.
        Blood. 1997; 89: 776-779
        • Macy E.
        • Bulpitt K.
        • Champlin R.E.
        • Saxon A.
        Anaphylaxis to infusion of autologous bone marrow: an apparent reaction to self, mediated by IgE antibody to bovine serum albumin.
        J Allergy Clin Immunol. 1989; 83: 871-875
        • Mackensen A.
        • Drager R.
        • Schlesier M.
        • Mertelsmann R.
        • Lindemann A.
        Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells.
        Cancer Immunol Immunother. 2000; 49: 152-156
        • Lee D.W.
        • Kochenderfer J.N.
        • Stetler-Stevenson M.
        • Cui Y.K.
        • Delbrook C.
        • Feldman S.A.
        • et al.
        T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.
        Lancet. 2015; 385: 517-528
        • Kochenderfer J.N.
        • Wilson W.H.
        • Janik J.E.
        • Dudley M.E.
        • Stetler-Stevenson M.
        • Feldman S.A.
        • et al.
        Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.
        Blood. 2010; 116: 4099-4102
        • Ali S.A.
        • Shi V.
        • Maric I.
        • Wang M.
        • Stroncek D.F.
        • Rose J.J.
        • et al.
        T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.
        Blood. 2016; 128: 1688-1700
        • Wood L.V.
        • Fojo A.
        • Roberson B.D.
        • Hughes M.S.
        • Dahut W.
        • Gulley J.L.
        • et al.
        TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer.
        Oncoimmunology. 2016; 5 (e1197459)
        • Slamon D.J.
        • Godolphin W.
        • Jones L.A.
        • Holt J.A.
        • Wong S.G.
        • Keith D.E.
        • et al.
        Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
        Science. 1989; 244: 707-712
        • Simon R.
        • Lam A.
        • Li M.C.
        • Ngan M.
        • Menenzes S.
        • Zhao Y.
        Analysis of gene expression data using BRB-ArrayTools.
        Cancer Inform. 2007; 3: 11-17
        • Tibshirani R.
        • Hastie T.
        • Narasimhan B.
        • Chu G.
        Diagnosis of multiple cancer types by shrunken centroids of gene expression.
        Proc Natl Acad Sci USA. 2002; 99: 6567-6572
        • Lopez-Gordo E.
        • Podgorski I.I.
        • Downes N.
        • Alemany R.
        Circumventing antivector immunity: potential use of nonhuman adenoviral vectors.
        Hum Gene Ther. 2014; 25: 285-300
        • Nayak S.
        • Herzog R.W.
        Progress and prospects: immune responses to viral vectors.
        Gene Ther. 2010; 17: 295-304
        • Ahi Y.S.
        • Bangari D.S.
        • Mittal S.K.
        Adenoviral vector immunity: its implications and circumvention strategies.
        Curr Gene Ther. 2011; 11: 307-320
        • Zhang W.F.
        • Wu F.L.
        • Shao H.W.
        • Wang T.
        • Huang X.T.
        • Li W.L.
        • et al.
        Chimeric adenoviral vector Ad5F35L containing the Ad5 natural long-shaft exhibits efficient gene transfer into human T lymphocytes.
        J Virol Methods. 2013; 194: 52-59
        • Zhang W.F.
        • Shao H.W.
        • Wu F.L.
        • Xie X.
        • Li Z.M.
        • Bo H.B.
        • et al.
        Influence of cell physiological state on gene delivery to T lymphocytes by chimeric adenovirus Ad5F35.
        Sci Rep. 2016; 6: 22688